Skip to main content

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy ofEfgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney TransplantRecipients with Antibody-Mediated Rejection

Open
  • Protocol code: ARGX-113-2302
  • EudraCT code: No aplica
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Moreso Mateos, Francesc
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II